NASCSA News

Optional page description text area...

Header Content Region

Insert text, image or banner ads here, or just delete this text and leave this area blank!

portfolio1 portfolio2 portfolio3 portfolio4

Heading 1

This is an example of the content for a specific image in the Nivo slider. Provide a short description of the image here....

Heading 2

This is an example of the content for a specific image in the Nivo slider. Provide a short description of the image here....

Heading 3

This is an example of the content for a specific image in the Nivo slider. Provide a short description of the image here....

Heading 4

This is an example of the content for a specific image in the Nivo slider. Provide a short description of the image here....

get in touch



Wednesday - February 8, 2017 1:34 pm
View roundtable disscussion concerning heroin and synthetic drugs Continue reading →
FDA Requires Strong Warnings
Thursday - September 1, 2016 11:46 am     A+ | a-
Link to this article: http://www.nascsa.org/news/BreakingNews/nascsaBreakingNews9.1.16.pdf

FDA Requires Strong Warnings for Opioid Analgesics, RX Opioid Cough Products, and Benzodiazepines
After an extensive review of the latest scientific evidence, the U.S. Food and Drug Administration announced today that it is requiring class-wide changes to drug labeling, including patient information, to help inform health care providers and patients of the serious risks associated with the combined use of certain opioid medications and a class of central nervous system depressant drugs called benzodiazepines.

slide up button
NASCSA - Copyright 2012 - All Rights Reserved